In patient #463 (Fig. 6e), who received quizartinib as salvage treatment for refractory AML with the FLT3-ITD mutation, clones harboring EZH2D657A (VAF, 51.3%), NRASG13D (VAF, 30.4%), and FLT3-ITD (VAF, 57.7%) were detected when quizartinib was initially administered. The gene discussed is FLT3; the disease is acute myeloid leukemia.